| Date Filed | Type | Description |
| 08/14/2023 |
4
| Collier Kathryn J (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| Witz Pascale (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| Rosen Hugh (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| RASTETTER WILLIAM H (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| PAPADOPOULOS STELIOS (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| Nunn Jason Raleigh (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| Klassen Preston (President & Head of R & D) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 225,000 options to buy
@ $1.36, valued at
$306k
|
|
| 08/14/2023 |
4
| Huang Alice Shih-hou (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| CALSADA CRISPINA (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 375,000 options to buy
@ $1.36, valued at
$510k
|
|
| 08/14/2023 |
4
| Hagan Joseph P (President and CEO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 1,312,500 options to buy
@ $1.36, valued at
$1.8M
|
|
| 08/14/2023 |
4
| BALTIMORE DAVID (Director) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.36, valued at
$20.4k
|
|
| 08/14/2023 |
4
| Aker Christopher Ray (Sr. VP & General Counsel) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 393,750 options to buy
@ $1.36, valued at
$535.5k
|
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/12/2023 |
4
| Klassen Preston (President & Head of R & D) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 350,000 options to buy
@ $1.46, valued at
$511k
|
|
| 06/12/2023 |
3
| Klassen Preston (President & Head of R & D) has filed a Form 3 on Regulus Therapeutics Inc. |
| 06/12/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/12/2023 |
SC 13D/A
| Growth Equity Opportunities V, LLC reports a 10% stake in Regulus Therapeutics Inc. |
| 05/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 19.9% stake in REGULUS THERAPEUTICS, INC. |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 17.2% stake in REGULUS THERAPEUTICS, INC. |
| 01/31/2023 |
SC 13G/A
| VICTORY CAPITAL MANAGEMENT INC reports a 5% stake in Regulus Therapeutics Inc. |
| 01/17/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|